FONTANA, DILETTA
FONTANA, DILETTA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia
2014 Donadoni, C; Piazza, R; Fontana, D; Parmiani, A; Pirola, A; Redaelli, S; Signore, G; Piazza, V; Malcovati, L; Spinelli, R; Magistroni, V; Gaipa, G; Peronaci, M; Morotti, A; Panuzzo, C; Saglio, G; Elli, E; Usala, E; Kim, D; Rea, D; Zervakis, K; Viniou, N; Symeonidis, A; Becker, H; Boultwood, J; Campiotti, L; Carrabba, M; Bignell, G; Papaemmanuil, E; Campbell, P; Cazzola, M; GAMBACORTI PASSERINI, C
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells
2014 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; Gambacorti-Passerini, C
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors
2015 Mologni, L; Ceccon, M; Fontana, D; Pirola, A; Piazza, R; Gambacorti-Passerini, C
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia
2015 GAMBACORTI PASSERINI, C; Donadoni, C; Parmiani, A; Pirola, A; Redaelli, S; Signore, G; Piazza, V; Malcovati, L; Fontana, D; Spinelli, R; Magistroni, V; Gaipa, G; Peronaci, M; Morotti, A; Panuzzo, C; Saglio, G; Usala, E; Kim, D; Rea, D; Zervakis, K; Viniou, N; Symeonidis, A; Becker, H; Boultwood, J; Campiotti, L; Carrabba, M; Elli, E; Bignell, G; Papaemmanuil, E; Campbell, P; Cazzola, M; Piazza, R
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia
2015 Niro, A; Piazza, R; Merati, G; Pirola, A; Donadoni, C; Fontana, D; Redaelli, S; Mezzatesta, C; Renso, R; Farina, F; Rea, D; Gambacorti-Passerini, C
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia
2015 Niro, A; Piazza, R; Merati, G; Pirola, A; Donadoni, C; Fontana, D; Redaelli, S; Mezzatesta, C; Renso, R; Cecchetti, C; Rea, D; Gambacorti-Passerini, C
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; GAMBACORTI PASSERINI, C
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
2015 Fontana, D; Ceccon, M; GAMBACORTI PASSERINI, C; Mologni, L
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients
2015 Piazza, R; Cecchetti, C; Pirola, A; Donandoni, C; Fontana, D; Mezzatesta, C; Magistroni, V; Bianchi, B; Borin, L; Fumagalli, M; GAMBACORTI PASSERINI, C
Role of somatic ETNK1 mutation in the mitochondrial activity
2017 Fontana, D; Bertagna, M; Mauri, M; Bossi, M; Citterio, S; Crescenzi, B; Signore, G; Piazza, V; Mecucci, C; Cavaletti, G; Gambacorti Passerini, C; Piazza, R
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates
2017 Farina, F; Ceccon, M; Mori, S; Verga, L; Borin, L; Mologni, L; Fontana, D; Geeta, G; Piazza, R; Gambacorti-Passerini, C
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity
2018 Fontana, D; Mauri, M; Niro, A; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Signore, G; Piazza, V; Mecucci, C; Cavaletti, G; Rea, D; Gambacorti-Passerini, C; Piazza, R
ETNK1 mutations increase mitochondrial activity and promote DNA damage through ROS production
2018 Fontana, D; Mauri, M; Niro, A; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Signore, G; Piazza, V; Fanelli, F; Mecucci, C; Cavaletti, G; Rea, D; Gambacorti Passerini, C; Piazza, R
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION
2018 Fontana, D; Mauri, M; Niro, A; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Signore, G; Piazza, V; Mecucci, C; Cavaletti, G; Rea, D; Gambacorti-Passerini, C; Piazza, R
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039)
2018 Mah, S; Park, J; Jung, H; Ahn, K; Choi, S; Tae, H; Jung, K; Rho, J; Lee, J; Passerini, C; Fontana, D; Hong, S; Hong, S
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis
2019 Mauri, M; Elli, E; D'Aliberti, D; Crespiatico, I; Nava, M; Massimino, L; Sharma, G; Fontana, D; Redaelli, S; Bombelli, S; Pelucchi, S; Perego, R; Piperno, A; Gambacorti Passerini, C; Piazza, R
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients
2019 Fontana, D; Ramazzotti, D; Aroldi, A; Niro, A; Massimino, L; Rea, D; Stagno, F; Martino, B; Campiotti, L; Caocci, G; Elli, E; Fumagalli, M; Ciceri, F; Piazza, R; GAMBACORTI PASSERINI, C
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia
2019 Fontana, D
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
2019 Magistroni, V; Mauri, M; D'Aliberti, D; Mezzatesta, C; Crespiatico, I; Nava, M; Fontana, D; Sharma, N; Parker, W; Schreiber, A; Yeung, D; Pirola, A; Redaelli, S; Massimino, L; Wang, P; Khandelwal, P; Citterio, S; Viltadi, M; Bombelli, S; Rigolio, R; Perego, R; Boultwood, J; Morotti, A; Saglio, G; Dong-Wook, K; Branford, S; Gambacorti Passerini, C; Piazza, R